ClinicalTrials.gg
Active, not recruitingNCT06845202Updated Nov 16, 2026

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

A Phase 1/2 interventional study of ALN-4324 and Placebo in Obese or Overweight Healthy Volunteers and Type 2 Diabetes Mellitus (T2DM), sponsored by Alnylam Pharmaceuticals. Active, not recruiting at 22 sites in 6 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to:

  • evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324
  • evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
02

Conditions studied

  • Obese or Overweight Healthy Volunteers
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • siRNA
  • RNAi therepeutic
03

In context

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 105 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Has a (BMI) of ≥27 kg/m\^2 and \<40 kg/m\^2

Part B:

  • Is an adult patient with a confirmed diagnosis of T2DM
  • Has a (HbA1c) ≥7% to \<10.5%
  • Has a BMI of ≥25 kg/m\^2 and \<45 kg/m\^2
  • Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i)

Exclusion criteria

Exclusion Criteria:

Part A:

  • Has known (HIV) infection; or known current or chronic virus or virus infection

Part B:

  • Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i

Note: other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Part A: ALN-4324

    Participants will be administered a single dose of ALN-4324.

    Drug: ALN-4324

  • Placebo comparator
    Part A: Placebo

    Participants will be administered a single dose of placebo.

    Drug: Placebo

  • Experimental
    Part B: ALN-4324

    Participants will be administered multiple doses of ALN-4324

    Drug: ALN-4324

  • Placebo comparator
    Part B: Placebo

    Participants will be administered multiple doses of placebo

    Drug: Placebo

Interventions

  • DrugALN-4324

    ALN-4324 will be administered subcutaneously (SC)

  • DrugPlacebo

    Placebo will be administered SC

06

What researchers measure

Primary outcomes

  1. Part A: Frequency of Adverse Events (AEs)

    Time frame: Up to 9 months

  2. Part B: Frequency of Adverse Events

    Time frame: Up to 12 months

Secondary outcomes

  1. Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-4324 in Plasma

    Time frame: Predose and up to 3 days postdose

  2. Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-4324 in Plasma

    Time frame: Predose and up to 3 days postdose

  3. Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-4324 in Plasma

    Time frame: Predose and up to 3 days postdose

  4. Part A: Fraction of ALN-4324 excreted in urine

    Time frame: Predose and up to 24 hours postdose (fe)

  5. Part B: Change from Baseline in HbA1c

    Time frame: Baseline up to 6 months

  6. Part B: Response to Glucose Tolerance Test

    Time frame: Predose and up to 2 hours postdose

  7. Part B: Concentrations of ALN-4324 in Plasma

    Time frame: Predose and up to 4 hours postdose

07

Study locations

22 sites
  • Clinical Trial Site
    Montclair, California 91763, United States
  • Clinical Trial Site
    Washington D.C., District of Columbia 20009, United States
  • Clinical Trial Site
    Miami, Florida 33126, United States
  • Clinical Trial Site
    Marlton, New Jersey 08053, United States
  • Clinical Trial Site
    Monroe, North Carolina 28112, United States
  • Clinical Trial Site
    Dallas, Texas 75230, United States
  • Clinical Trial Site
    Dallas, Texas 75246, United States
  • Clinical Trial Site
    Buenos Aires, C1060, Argentina
  • Clinical Trial Site
    Buenos Aires, C1061AAE, Argentina
  • Clinical Trial Site
    Buenos Aires, C1061, Argentina
  • Clinical Trial Site
    San Miguel de Tucumán, T4000IHE, Argentina
  • Clinical Trial Site
    Concord, L4K 4M2, Canada
  • Clinical Trial Site
    Mount Royal, H3P 3P1, Canada
  • Clinical Trial Site
    Vancouver, V5Y 3W2, Canada
  • Clinical Trial Site
    Santiago, 7500710, Chile
  • Clinical Trial Site
    Santiago, 7770086, Chile
  • Clinical Trial Site
    Santiago, 8320000, Chile
  • Clinical Trial Site
    Essen, 45355, Germany
  • Clinical Trial Site
    Gdansk, 80-546, Poland
  • Clinical Trial Site
    Tarnów, 33-100, Poland
  • Clinical Trial Site
    Warsaw, 02-507, Poland
  • Clinical Trial Site
    Wroclaw, 51-162, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2027, 29 months after the start.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartActual
Mar 3, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06845202
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Mar 3, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion